-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：HUBB公佈了強勁的第一季財報，每股盈餘（EPS）為3.93美元（年成長16%），高於市場普遍預期的3.86美元。淨銷售額成長11%至16億美元，主要得益於資料中心和公用事業基礎設施支出加速成長帶來的8.2%的強勁內生成長。公用事業電網現代化投資和資料中心對電氣產品的持續需求推動了績效的超預期成長。管理層上調了2026年業績預期，目前預計總銷售額將增長8%-11%，其中包括6%-9%的內生增長，調整後每股收益預計為19.30-19.85美元。公用事業解決方案業務成長11%至9.49億美元，主要得益於電網基礎設施業務約18%的強勁成長，這主要得益於公用事業公司對輸電和變電站基礎設施的投資；電氣解決方案業務增長12%至5.68億美元，主要得益於數據中心業務的持續強勁增長。經調整後的營業利潤率增長了 110 個基點，達到 19.8%，其中公用事業解決方案利潤率因銷量增長和定價舉措而飆升 190 個基點，達到 21.8%，而電氣解決方案利潤率由於成本壓力和重組投資而壓縮了 30 個基點，達到 16.4%。
Related Articles
Research
Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.
$BIO
Asia
ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue
ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.
$ASX:RMD
Research
Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.
$GDDY